Mineralys Therapeutics, Inc. Common Stock (MLYS) — Strategic Asset Allocation Index
Mineralys Therapeutics, Inc. Common Stock (MLYS) has a Strategic Asset Allocation Index of 0.0% as of December 2024. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $191.26 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Mineralys Therapeutics, Inc. Common Stoc balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Mineralys Therapeutics, Inc. Common Stock Strategic Asset Allocation Index (2023–2024)
This chart shows how Mineralys Therapeutics, Inc. Common Stock's Strategic Asset Allocation Index has evolved across 2 annual periods from 2023 to 2024. As of December 2024, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $191.26 Million USD. For live market cap and overall valuation, see MLYS company net worth.
Annual Strategic Asset Allocation Index for Mineralys Therapeutics, Inc. Common Stock (2023–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Mineralys Therapeutics, Inc. Common Stock from 2023 to 2024, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Mineralys Therapeutics, Inc. Common Stoc (MLYS) shareholders funds for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 0.0% | $0.00 | $- | $0.00 | $191.26 Million | ▼ -1.0 pp |
| 2023 | 1.0% | $2.48 Million | $- | $2.48 Million | $241.15 Million | — |